Consequently, transitioning from the EFV- to DTG-based regimen appears to lower the levels of the platelet activation markers, sCD40L and RANTES, thereby potentially reducing platelet activation and subsequent inflammatory responses associated with increased risk of developing chronic diseases related to atherosclerosis [50]. This evidence concerns the gene CD40LG and atherosclerosis.